Elective total hip arthroplasty and total knee arthroplasty are associated with a high risk of postoperative venous thromboembolism. Traditionally, antithrombotic prophylaxis has been administered during the hospital stay. However, with patients spending less time in the hospital after surgery, there is a need to continue thromboprophylaxis beyond hospital discharge. The current recommendation for prophylaxis in total joint arthroplasty patients is a minimum of 10 days, with extended prophylaxis up to 28 to 35 days following total hip arthroplasty. Prophylaxis with low-molecular-weight heparins for approximately 4 weeks following hip arthroplasty has resulted in clinically significant reductions in the incidence of venographically confirmed deep vein thrombosis. Currently, no data support extended thromboprophylaxis beyond 10 days following total knee arthroplasty. Using weighted risk factors to assess individual risk for venous thromboembolism can help the physician determine the optimal duration of prophylaxis.
E lective total hip arthroplasty (THA) and total knee arthroplasty (TKA) carry a high risk of postoperative venous thromboembolism (VTE), a serious and potentially fatal condition when it presents as deep vein thrombosis (DVT) and pulmonary embolism (PE). 1 Prophylaxis to prevent DVT is an essential component of routine management in patients who have had THA and TKA. DVT is a silent disease, and clinical diagnosis is unreliable. 2 Postoperative morbidity, economic costs, and potential for mortality are additional factors that support extended-duration prophylaxis to prevent DVT. 1 Several prophylactic antithrombotic agents, including low-molecular-weight heparins (LMWHs), 3, 4 oral vitamin K antagonists (eg, warfarin), 5, 6 and the synthetic factor-Xa inhibitor fondaparinux, 7 are safe and effective for patients who have had THA or TKA. Although the use of preventive antithrombotic therapy has substantially reduced the incidence of postoperative VTE after THA and TKA, clinically important questions remain regarding the safest, most efficacious, and most costeffective use of thromboprophylaxis in this setting.
Prophylaxis for VTE following surgery traditionally has been started on the day of surgery and continued until hospital discharge, with a typical dosing period of 7 to 10 days. The recent trend toward shorter periods of postoperative hospitalization 8 has limited the duration of supervised prophylactic treatment. However, DVT and PE can occur up to 3 to 4 weeks following orthopaedic surgery. [9] [10] [11] Thus, although it is clear that patients require thromboprophylaxis, the optimal duration of prophylaxis for VTE following surgery remains unclear. Challenges include identifying patients who would benefit from extended prophylaxis and determining a safe, efficacious, and cost-effective postoperative treatment duration.
Controversies

Surrounding Extended Thromboprophylaxis
The optimal duration of prophylaxis is critical in the postoperative management of orthopaedic patients because of their risk of DVT and PE. 12, 13 Reduced hospital stays following orthopaedic surgical procedures, in addition to the current trend toward early transfer of postoperative patients to home or to a convalescent facility, 13 may result in suboptimal thromboprophylaxis. Thus, extending prophylaxis beyond the hospital stay may be warranted to address the continued risk of VTE in these patients. 1, 4, 10 At present, the relationship between venographic and symptomatic VTE is unknown because of several factors: the silent nature of VTE; the difficulties in reliably diagnosing DVT and PE, even when symptomatic; and the clinical significance of silent events that are detected solely by objective methods. However, clinical trials of thromboprophylaxis indicate that symptomatic VTE is rare when DVT is detected and treated early. 14 The relationship between venographic and symptomatic VTE has direct bearing on decisions related to the duration of postoperative prophylaxis because selection of an appropriate and reliable clinical end point for evaluating performance is critical in order to determine true benefit and risk.
In a study of VTE incidence and PE mortality in 1,162 consecutive THA patients, a large discrepancy was found between the observed symptomatic DVT rate (1.9% by day 20) 15 and the high overall DVT rate (54% by day 7-14) reported in clinical trials using universal screening venography. 1 Although studies evaluating the benefit of extended VTE prophylaxis after orthopaedic surgery demonstrate an increased incidence of venographically detected DVT in patients treated with placebo, these same studies indicate a low incidence of clinically overt events in both the treatment and placebo groups. 16 Because most thrombi lyse spontaneously and because it has not been established that asymptomatic DVT leads to postthrombotic syndrome, some suggest that symptomatic events are the most appropriate end point for determining true clinical efficacy in DVT prevention studies. The accuracy of symptomatic events as a clinical end point has not been studied, however, because of the large study populations needed to detect a reduction in event rate of only 2% to 3%.
Some in the medical community suggest that most VTEs resolve without causing serious clinical sequelae; others support a link between DVT formation per se and the potential for significant morbidity and mortality. Results of a metaanalysis of six studies 9, 10, [17] [18] [19] [20] examining the relationship between clinical events and prolonged prophylaxis with either LMWH or warfarin in 1,376 patients who had undergone THA or TKA indicated that the reduction in risk of developing symptomatic VTE (51%, P = 0.008) was similar to the reduction in risk of venographically diagnosed DVT (50%, P = 0.009). 21 These results support the use of venographically diagnosed DVT as a good surrogate end point for symptomatic events.
Additionally, undiagnosed asymptomatic VTE may lead to chronic venous disease or recurrent VTE. A recent systematic review and metaanalysis that included total joint arthroplasty and abdominal surgery indicated that patients with asymptomatic DVT had an increased risk of late development of postthrombotic syndrome (PTS) compared with patients without postoperative DVT (relative risk, 1.58; 95% confidence interval, 1.24-2.02; P < 0.0005). 22 This increased risk also was demonstrated for the total joint arthroplasty subgroup (relative risk, 2.36; 95% confidence interval, 1.64-3.41; P < 0.00001). 22 However, symptomatic PTS was not associated with asymptomatic DVT and was found to be uncommon following THA and TKA in patients with postoperative DVT who received 6 to 12 weeks of anticoagulant therapy. 23 The likely explanation is that prophylaxis not only reduces the incidence of VTE but also the size of the thrombi, such that smaller thrombi are likely to cause less valvular damage and obstruction associated with PTS.
Incidence of VTE Following Hospital Discharge After THA and TKA
The thrombogenic processes that can lead to VTE begin early during joint arthroplasty surgery. 24 The subsequent timing of clinically overt VTE and PE events shows a difference between THA and TKA. 11, 25 Symptomatic VTE occurs much earlier following TKA; half of the events occur within 7 days, compared with 17 days following THA, suggesting differences in pathogenesis or natural history between the two.
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The difference between timing of VTE events after THA and TKA is also reflected in the effectiveness of extended thromboprophylaxis. To date, nine randomized studies 9, 10, [17] [18] [19] [20] [26] [27] [28] have evaluated the efficacy and safety of extended prophylaxis with a variety of drugs in patients who have undergone either THA or TKA ( Table 1) . Seven of these studies were restricted to THA populations, 9, 10, [17] [18] [19] 27, 28 and two involved both THA and TKA populations. 20, 26 Six of the nine studies 9, 10, [17] [18] [19] 26 used venographic end points as the primary efficacy outcome; these results are summarized in Figure 1 . In the remaining three studies, either symptomatic VTE 20 or ultrasonographic DVT detection 27, 28 was used to determine efficacy. Overall, the studies of extended-duration prophylaxis in the THA populations demonstrated a significant reduction (P < 0.05) in the rate of asymptomatic VTE after hospital discharge. The value of extended-duration prophylaxis following TKA has not been demonstrated.
Extended-Duration Thromboprophylaxis
Following THA and TKA
Total Hip Arthroplasty
Low-Molecular-Weight Heparins
Studies of prolonged thromboprophylaxis with LMWH have focused primarily on THA patients. These studies have demonstrated a significant reduction (P < 0.05) in the incidence of venographically confirmed DVT with LMWH treatment compared with placebo in this surgical population. 9, 10, [17] [18] [19] 26 Although clinical study has focused on enoxaparin and dalteparin, a single study of extended ardeparin prophylaxis has been reported. Ardeparin was administered for up to 6 weeks after surgery (100 IU/kg once daily) in 1,195 patients after either THA or TKA. 20 Compared with ardeparin administration for 4 to 10 days, no benefit was shown with extended prophylaxis for either procedure. 20 The authors of this study used acute symptomatic, objectively documented VTE or all-cause death as an end point rather than venography. Ardeparin is no longer available for distribution in the United States.
The use of extended-duration enoxaparin prophylaxis in patients undergoing THA was evaluated in three prospective, double-blind, placebo-controlled studies. 10, 17, 26 In all three studies, the extended prophylaxis regimen was enoxaparin (or placebo) 40 mg once daily for 21 days. The initial standard enoxaparin prophylaxis regimen was 40 mg/d subcutaneously for 13 to 15 days, 10 40 mg/d subcutaneously for 7 to 10 days with a 40 mg subcutaneous dose given 12 hours preoperatively, 17 or 30 mg subcutaneously every 12 hours starting 12 to 24 hours postoperatively for a duration of 7 to 10 days. 26 All three studies demonstrated that, for patients undergoing THA, extended enoxaparin prophylaxis led to a significant reduction (P < 0.001 to P = 0.018) in the incidence of total venographic DVT at the end of the treatment period (range, 7% to 18%) compared with placebo (range, 19% to 39%) ( Figure  1, A) . In addition, two of these studies 17,26 demonstrated significant reduction in the incidence of venographic proximal DVT, from 13% to 24% with placebo to 3% to 7% with extended enoxaparin prophylaxis (P < 0.001). The third study 10 showed no significant reduction in proximal DVT incidence, but that result may reflect a difference in study design. Planes et al 10 performed screening venography, and patients with a positive venogram were excluded before randomization.
The authors of the three studies also reported on the safety of extended enoxaparin prophylaxis. In two studies, 10, 17 minor hemorrhagic complications, primarily involving the injection site, were observed 4 to 5 times more frequently with enoxaparin than with placebo. In the third study, 26 no differences in the low incidence of all hemorrhagic complications were found for the enoxaparin and placebo cohorts, but the one bleeding event in the placebo group was considered major.
Three studies have evaluated extended LMWH prophylaxis with dalteparin in patients after THA. 9, 18, 19 Two employed similar dosing regimens in the initial prophylaxis period (5,000 IU/d begun preoperatively and continued for 7 days) as well as in the period of extended dalteparin prophylaxis (5,000 IU/d or placebo, up to postoperative day 35). 9, 18 Both studies demonstrated significant reductions in the incidence of total venographic DVT at the end of the extended dalteparin prophylaxis period relative to placebo, with decreases to 19% from 32% (P = 0.034) 9 and to 4% from 12% (P = 0.039) 18 ( Figure 1, A) . A limitation of these two studies is that prophylaxis was begun preoperatively, which is uncommon in the United States.
The third study, which compared extended dalteparin prophylaxis with standard warfarin prophylaxis followed by placebo, included one group treated with preoperative dalteparin and one treated with early postoperative dalteparin. 19 In both prophylaxis regimens, LMWH treatment resulted in a significant reduction in total venographic DVT incidence compared with placebo, from 37% to 20% (P < 0.001) (Figure 1, A) , as well as in proximal DVT incidence, from 9% to 3% (P < 0.002). 19 Extended dalteparin prophylaxis was associated with a higher frequency of minor bleeding complications than was placebo, 9 particularly injection-site bruising. 19 However, major bleeding events attributed to the LMWH treatment occurred rarely 9 or not at all. 18, 19 Based on these collective findings, extended-duration LMWH prophylaxis appears to be relatively safe. Heparin-induced thrombocytopenia is a rare complication with LMWHs; no incidences occurred in any of these studies. 9, 10, [17] [18] [19] 26 Compliance with a once-daily self-injected subcutaneous dose was extremely high. However, one weakness of these trials is that patients usually received prophylaxis for only 7 to 10 days. Trials that compare 10 to 14 days of prophylaxis with 28 to 35 days and evaluate symptomatic events would Incidence of venographic deep vein thrombosis (DVT) following hospital discharge in patients treated with either extended prophylaxis or placebo after total hip arthroplasty or total knee arthroplasty. Venography was the efficacy outcome measure in all trials; overall DVT incidence recorded on assessable patients are indicated. A, Hip arthroplasty. All of the trials in hip arthroplasty populations evaluated extended prophylaxis with low-molecular-weight heparins (ie, enoxaparin, dalteparin). B, Knee arthroplasty. Enoxaparin was evaluated in the knee arthroplasty trial. * = overall VTE, NS = not statistically significant, VTE = venous thromboembolism provide valuable information for the clinician.
Warfarin
Relatively few controlled trials have examined the value of extended prophylaxis with warfarin following THA. 1 One study evaluated the combined effect of adjusted-dose warfarin and unfractionated heparin prophylaxis in patients following elective primary or revision THA. 28 Heparin (5,000 IU twice daily, starting the night of surgery) and warfarin (7.5 mg loading dose) were administered until patient international normalized ratio (INR) reached 2.0 to 3.0, at which time heparin was discontinued. The warfarin dose was adjusted to maintain a therapeutic INR for 4 weeks after surgery. Ultrasonography, a less sensitive method than venography for detecting DVT, was performed at 7 days and 4 weeks after surgery. The overall rate of DVT at postoperative day 7 (ie, at hospital discharge) was 5%, and the thrombosis rate at postoperative week 4 was 15% (8% proximal DVT, 7% distal DVT). Furthermore, patients who did not maintain an INR between 2.0 and 3.0 had a significantly higher rate (11%, P < 0.01) of DVT throughout the postoperative observation period, supporting the claim that appropriate anticoagulation is needed to minimize DVT risk after hospital discharge. The overall rate of bleeding complications was 6.4%. 28 A second study compared two treatment regimens of warfarin in patients who underwent THA. 27 Warfarin 5 mg/d was initiated on the second preoperative day; postoperatively, the dosage was adjusted to maintain an INR between 2.0 and 3.0. Patients were randomized to discontinue warfarin therapy at the time of hospital discharge (control group) or to continue warfarin for 4 more weeks. In this study, 27 as in the one by Caprini et al, 28 DVT detected by ultrasonography was the primary efficacy outcome measure. The confirmed VTE rates after 4 weeks were 5.1% for the control group (4.5% DVT, 0.6% PE) and 0.5% (DVT) for the extended warfarin prophylaxis group.
In both studies that assessed the benefits of extended warfarin therapy in the THA population, 27 ,28 the DVT rates observed were relatively lower than the rates found in the studies of extended-duration prophylaxis with enoxaparin and dalteparin in the same patient population. These comparative findings may reflect the differences in sensitivity of the DVT detection methods employed in the respective studies-ultrasonography versus venographywith the more sensitive technique of venography used in the studies of extended LMWH prophylaxis.
Fondaparinux
Fondaparinux, an indirect factor Xa inhibitor, is the most recent antithrombotic drug to be approved for the prevention of VTE in patients who have undergone either THA or TKA. Phase III trials in both of these surgical settings [29] [30] [31] demonstrated that, overall, fondaparinux administration led to a 45.3% reduction in VTE risk relative to enoxaparin after THA, and a 63.1% reduction in risk relative to enoxaparin after TKA, with no statistical increase in clinically relevant bleeding. 7 A recent post hoc analysis of the entire phase III trial program database indicates that the efficacy of fondaparinux increases with longer treatment duration. 32, 33 Prophylaxis with fondaparinux for 9 to 11 days (11 days was the longest duration evaluated) provided significantly greater efficacy (P < 0.001) compared with prophylaxis for 6 to 8 days or ≤5 days, with VTE incidences of 5.2%, 6.7%, and 8.7%, respectively. 32, 33 In addition, major bleeding events occurred less frequently with longer prophylaxis duration, based on event rates of 0.1% at 9 to 11 days, 0.3% at 6 to 8 days, and 1.8% at ≤5 days. In this study, enoxaparin efficacy and safety also increased significantly (P = 0.0025) with longer duration (9-11 days). 32, 33 A serious drawback of this post hoc analysis is the inclusion of a variety of surgical procedures, including THA, TKA, and hip fracture surgery, which disregards the differences in pathogenesis and natural history of VTE events among these procedures. The optimal duration of prophylaxis for THA and TKA has not been definitively established.
Meta-analyses of Extended VTE Prophylaxis Studies
A meta-analysis based on 13 studies published from 1974 through 1995 evaluated the incidence of lateoccurring symptomatic VTE in orthopaedic surgery patients discharged from the hospital with a negative venogram. 34 Among these patients, the cumulative incidence of clinically overt VTE was 1.3% (30/2,361 patients). Citing this low incidence, the authors concluded that extended prophylaxis is not justified. However, there were several limitations to their study: specifically, a requirement for negative venography at hospital discharge, the inclusion of trials involving anticoagulants no longer recommended for VTE prevention, inclusion of orthopaedic procedures in addition to THA and TKA, and a longer duration of in-hospital prophylaxis (mean, 12 days). 34 Thus, no definitive assessment could be made regarding patients with positive venography-the only accurate indicator of asymptomatic DVT. Patients with asymptomatic DVT are at risk of subsequently developing a symptomatic episode; the risk for DVT can persist for up to 2 months, particularly following high-risk surgery (eg, THA).
Support for extended prophylaxis is derived from a recent metaanalysis of nine trials comprising 3,999 patients who received extended prophylaxis with LMWHs or unfractionated heparin for 30 to 42 days after either THA or TKA. 35 In this meta-analysis, extendedduration prophylaxis significantly reduced the frequency of symptomatic (1.3% versus 3.3%) and asymptomatic (9.6% versus 19.6%) VTE compared with placebo. The risk reduction was greater for patients undergoing THA (67%) than for those undergoing TKA (26%). This risk reduction translated into an additional decrease of 20 symptomatic events per 1,000 treated patients after THA and TKA.
Further support for extending prophylaxis comes from another metaanalysis of six trials (n = 1,583) comparing the efficacy of LMWH with placebo in patients undergoing THA. 36 This evaluation showed that extending LMWH prophylaxis after discharge (19 to 29 days) compared with out-of-hospital placebo was significantly more effective in reducing overall DVT (7.9% versus 22.5%, P < 0.001), proximal DVT (3.0% versus 11.2%, P < 0.001), and symptomatic DVT (1.4% versus. 4.2%, P < 0.001).
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Duration of Extended VTE Prophylaxis Following Total Hip Arthroplasty
Most of the extended-duration VTE prophylaxis trials show variability in the duration of the inhospital prophylaxis period (Table 1) . Postoperative duration of hospital stay varies from hospital to hospital, and practices change over time; thus, determining an optimal total period of prophylaxis following THA is important in standardizing and improving patient care. It is known that at least 10 days of postoperative prophylaxis is safe and effective following THA. Prolonged prophylaxis is beneficial, with reduced VTE incidence after 35 days of prophylaxis compared with either 7 days 9,18 or 13 to 15 days. 10 The optimal duration of VTE prophylaxis following THA beyond 10 to 14 days remains to be determined.
Total Knee Arthroplasty
Further studies are warranted to elucidate whether the benefits of extending thromboprophylaxis for 21 days apply to patients undergoing TKA. Comp et al 26 reported no significant difference in total (Figure 1,  B) or proximal venographic DVT rates with enoxaparin relative to placebo (21% versus 26%, and 5% versus 8%, respectively) in the TKA patient group. Heit et al 20 studied extended ardeparin prophylaxis (100 IU/kg once daily) up to 6 weeks after surgery in 1,195 patients who had undergone either THA or TKA. With both procedures, extended prophylaxis was no more effective than 4 to 10 days of prophylaxis.
A meta-analysis of these two trials showed a risk reduction of asymptomatic (18%) and symptomatic (26%) VTE following TKA. 32 These reductions were not statistically significant; this lack of significance was likely influenced by an estimate based on aggregate data from only two studies with a total of just seven events. No study to date has shown that prolonging prophylaxis for more than 10 days is necessary after TKA. Further studies on the optimal duration of prophylaxis in this subpopulation would be of value.
Current Guidelines for Venous Thromboembolism Prevention in Major Orthopaedic Surgery
The seventh American College of Chest Physicians consensus guidelines on the prevention of VTE were developed using evidence-based medicine. 1 With expert input from orthopaedic surgeons, the available literature was reviewed, and graded recommendations for prophylaxis were made based on the quality of the data. Grade 1 recommendations are made when the evidence of benefit or risk is clear; grade 2 recommendations are made when the evidence is less clear. The level of evidence is graded A (consistent results from randomized clinical trials), B (inconsistent results from randomized trials or major methodologic weaknesses), or C (observational studies or generalizations from randomized trials in one patient group to another group). A grade C+ recommendation is made when a generalization was considered to be secure or when the evidence from observational studies was overwhelmingly compelling.
For both THA and TKA, prophylaxis with LMWHs, warfarin, and factor Xa inhibitors received grade 1A recommendations for a minimum of 10 days. Extended prophylaxis for up to 28 to 35 days postoperatively is recommended for THA (1A) with LMWHs (1A), warfarin (1A), or factor Xa inhibitors (1C+). The American College of Chest Physicians makes an ungraded recommendation against the use of routine duplex ultrasonography at hospital discharge and during outpatient follow-up in determining the presence of asymptomatic DVT. 
Optimizing Therapy: Risk Factor Assessment
Knowledge of specific risk factors in the orthopaedic population forms the basis for the appropriate use and duration of prophylaxis. Clinical outcomes and cost effectiveness of VTE prophylaxis may be optimized by tailoring treatment to the level of risk of each patient.
During the past 20 years, several risk assessment models have been developed to assist physicians in determining appropriate prophylaxis; patients are stratified according to a certain level of risk. 1, [37] [38] [39] [40] [41] Most recently, Caprini et al 42 combined various components of the available risk assessment models and proposed a simple, self-contained scoring system for both surgical and medical patients that provides thromboprophylaxis recommenda-tions for each of four risk categories (low, moderate, high, very high). This scoring system has yet to be validated, however.
In general, risk factors are additive. For example, patients with transient risk factors (eg, surgery, trauma) who have had a prior VTE episode have an increased risk for primary and secondary VTE events. Patients with recent surgery requiring anesthesia have an 11-to 19.5-fold increase in their risk for VTE events. 43 The need for improved prophylaxis regimens is greatest in those most likely to experience a VTE event.
Although there are no true guidelines to direct physician decisions, the results from clinical studies have provided some indications for extended-duration prophylaxis. Optimal duration of VTE prophylaxis should be governed by individual patient risk factors. An increased number of risk factors clearly warrant extending VTE prophylaxis. Combining clinical judgment with a risk assessment tool allows the physician to prescribe appropriate therapy based on evidence-based recommendations and individual patient risk.
Summary
Elective THA and TKA are particularly strong risk factors for VTE. The benefits of pharmacologic prophylaxis in patients undergoing THA or TKA are clearly established and include a significant reduction in the incidence of postoperative VTE. THA and TKA differ in their time course of VTE occurrence following surgery, with longer extended risk after THA. With both procedures, at least 10 days of prophylaxis is safe and effective. Data indicate that extending prophylaxis for up to 4 weeks is beneficial after THA, although the optimal duration beyond 10 days remains to be determined. Currently, no data support extended prophylaxis following TKA; instead, optimal duration of VTE prophylaxis should be governed by individual patient risk. Further studies are needed that compare 10 to 14 days of prophylaxis with 28 to 35 days. Additional studies are needed to assess the development of symptomatic VTE with warfarin versus LMWHs or factor Xa inhibitors.
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